GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. - Wikidata - awgldk - TriplyDB

GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.

GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.

http://www.wikidata.org/entity/Q40462682

about

Down syndrome and leukemia: insights into leukemogenesis and translational targets Childhood acute myeloid leukaemia Prognosis and management of acute myeloid leukemia in patients with Down syndrome Transcription factor GATA-1 and Down syndrome leukemogenesis The GATA site-dependent hemogen promoter is transcriptionally regulated by GATA1 in hematopoietic and leukemia cells Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia GATA factor mutations in hematologic disease.The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia.CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells.Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology Acute megakaryoblastic leukemia in Down syndrome.Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia.Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.Myeloid Proliferations Associated with Down Syndrome.Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome Down syndrome with different hematological manifestations: a short series of 3 cases with review of literature.Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy Synergistic anti-leukemic interactions between ABT-199 and panobinostat in acute myeloid leukemia ex vivo RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia.Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome.Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.Unique clinical and biological features of leukemia in Down syndrome children.Haematopoietic development and leukaemia in Down syndrome.Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma.The promise of Janus kinase inhibitors in the treatment of hematological malignancies.Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.

P2860

Q26770335-A3CA7671-14D3-4880-9197-23F3E9EF4E38 Q27005960-4DD891B0-D6FF-4697-838A-31866CBE97FD Q27016577-53BCAEFE-8281-4995-8FC4-B427101B1D80 Q28251869-FEF7815D-CD4F-4040-98D7-1821AA3DA406 Q28293782-D8314AA5-4143-45F3-A988-6541BCBEFF36 Q28385690-7FD986C1-40EB-456B-8264-F22CB26D8671 Q33439175-6B768A9B-6BA8-4127-8859-65E622A55530 Q33698398-6AC277B6-8346-434A-91F6-CE4B17CCD5F2 Q33831971-448CE6DB-96F7-4079-977A-6FB4A08187B5 Q34081566-BCCDA0C9-27F9-4A2D-9A40-D4D90DC3B86C Q34318452-BABD2B8F-4922-4796-86A1-D48C04ADA054 Q34352858-B0D1C764-5218-441E-BA4C-3EFB98BF7C64 Q34544769-92B05A69-10F9-4D17-852E-974172EC9F58 Q34611232-04CE6A4A-7978-4AC3-8732-FB44F3F41B3E Q34703001-EF77DE80-4F05-406B-B83B-8473A77D4568 Q34849602-F943BF20-663A-4FA0-AFF2-F9B43764C4BB Q35007971-82732C23-D7A6-412A-81CE-F421E378EF30 Q35780831-36E39AAA-4784-4172-BCC1-8CFE27BCE1F7 Q35848677-F03F95A0-41C7-4C81-A859-6DC95A9DC873 Q36094977-C4C3D401-2D00-461E-AB88-4158A04451E3 Q36440331-E75D2D86-AE3F-43E1-BA8E-E69EB74509C5 Q36481252-E364C6B2-C8F8-4F66-AEA5-C5E5175AD32E Q36609265-D2CF5A24-7F99-4BED-9EEF-94868B6CAD05 Q36843733-F3E7AE54-F2A2-4D12-93C3-FC2D08DC4463 Q37142140-C48242B4-5E1E-4832-9636-4E229B6132FF Q37259709-52D4B17C-EF0E-409C-9C42-020C1F334D4E Q37293167-189F2E82-B392-40E6-B3C0-89D5684C26DF Q37372829-E7C1E7FD-3224-4C04-916D-1970184D4B5C Q37372833-CE4F35B5-BBAD-4C7A-B605-4955AB7B540E Q37376388-72A49E19-C159-473D-8C77-CE062D624CBA Q37427903-B8BDA662-2083-4DB1-9683-4CA35BCEAF68 Q37630747-46AC61DA-85AA-4F2A-B019-EEE189366F6C Q37701599-B03FA7CC-21B4-41A8-A1BD-B3A38347D09F Q37810271-AFB59B36-D163-4DE8-850C-9D786EEF1A69 Q38243161-3CFC6F2C-5BC5-4962-82E4-E08E0B8C8FF0 Q38733360-CA8D554D-16DD-4819-891F-115D3846373B Q38748709-F6B4D257-B2B4-4ABA-854D-F15966755595 Q38948573-B5A85917-A728-43F8-96EC-3DC57FE0616E Q39170500-C725D3D9-437D-478B-A209-D6382F03CFC0 Q41009977-22B4517C-E2A3-4FD5-917A-2CBC0EE3DC93

P2860

GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.

http://www.wikidata.org/entity/Q40462682

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

GATA1, cytidine deaminase, and ...... acute megakaryocytic leukemia.

@en

type

label

GATA1, cytidine deaminase, and ...... acute megakaryocytic leukemia.

@en

prefLabel

GATA1, cytidine deaminase, and ...... acute megakaryocytic leukemia.

@en

P1433

Q40462682-7BA54EA7-D467-4316-9FA3-CB0026E66684

P1476

Q40462682-DD9EAF5C-E4F5-4835-B7C7-B3A0F0690AF1

P2093

Q40462682-02D3E8E7-7078-4B3F-8A14-583AA7333EFF

Q40462682-38EA9864-8372-4135-BC6C-F207FC86BD79

Q40462682-3912CFC2-680F-4957-9EC1-CF80E02B8CB6

Q40462682-755B39EB-FA22-4A07-B2DF-E550513F2F0E

Q40462682-874B04FD-8C15-4619-84D2-599CC432442E

Q40462682-A473B521-5956-407C-80DB-278C31BE3849

Q40462682-A675A02B-D7F4-4712-80FE-D1AE4520DEB3

Q40462682-C414A241-82CC-4573-B344-4AD7A76020BA

Q40462682-EB47FC80-7CBE-4FDE-8F51-A0A7C0A91456

P2860

Q40462682-08E10EB8-989B-4A09-8240-5BBDD05464E5

Q40462682-1A330D15-D303-43EC-8ECE-9791A63674BC

Q40462682-3050C473-5C8D-4B2C-B22A-ECD8980BC4D2

Q40462682-5A2DD9D8-6C53-4219-B1B7-DF54E14577A4

Q40462682-69B5F4F7-7B94-46ED-B794-700396A81233

Q40462682-765C0B0D-FB99-4AE7-953E-9E89BBB3C6DD

Q40462682-CBF5ED12-2056-47C9-9375-089C260AE4E8

Q40462682-D4880954-11F7-440D-8FB2-8BF0C8C6124A

Q40462682-E98D03D8-3438-4384-997B-70F506C9FE3D

P304

Q40462682-10A7A8B1-B757-4974-AE26-9E5476327DC0

P31

Q40462682-340B5AD2-0040-438E-96B7-1E4A03AED075

P356

Q40462682-2AB9118B-FE6C-4834-AE59-2F2AE593CE5E

P407

Q40462682-1679C530-4A2D-4991-AAA9-01DF477D3B46

P433

Q40462682-85CE9AF2-1EC2-43D0-AE0B-892CA9EBE104

P478

Q40462682-615BF4DB-A542-4CF3-90A1-D6EA9AD4B8CF

P577

Q40462682-C1C828B6-CCCC-4966-A056-35CFED062C8D

P5875

Q40462682-A1A2111C-9497-4508-98F9-5F294507E0D3

P698

Q40462682-82B0A5F5-6830-4789-B53F-E0DDD5F8D149

P356

P1433

Journal of the National Cancer Institute

P1476

GATA1, cytidine deaminase, and ...... acute megakaryocytic leukemia.

@en

P2093

Dana A Tatman

http://www.w3.org/2001/XMLSchema#string

Jeffrey W Taub

http://www.w3.org/2001/XMLSchema#string

Larry H Matherly

http://www.w3.org/2001/XMLSchema#string

Mark L Stout

http://www.w3.org/2001/XMLSchema#string

Ronald L Thomas

http://www.w3.org/2001/XMLSchema#string

Steven Buck

http://www.w3.org/2001/XMLSchema#string

Tanya L Jensen

http://www.w3.org/2001/XMLSchema#string

Yaddanapudi Ravindranath

http://www.w3.org/2001/XMLSchema#string

Yubin Ge

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21

Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome

The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines

Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome.

GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.

Nucleoside analogues: mechanisms of drug resistance and reversal strategies.

Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder.

Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome.

An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome.

P304

226-231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJI026

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8045874

http://www.w3.org/2001/XMLSchema#string

P698

15687366

http://www.w3.org/2001/XMLSchema#string